Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

Collaboration between networks presents opportunities to increase analytical power and cross-validate findings. Multivariate analyses of 2 large, international datasets (MYSTIC and SENTRY) from the Global Advisory on Antibiotic Resistance Data program explored temporal, geographic, and demographic trends in Escherichia coli resistance from 1997 to 2001. Elevated rates of nonsusceptibility were seen in Latin America, southern Europe, and the western Pacific, and lower rates were seen in North America. For most antimicrobial drugs considered, nonsusceptibility was higher in isolates from men, older patients, and intensive care unit patients. Nonsusceptibility to ciprofloxacin was higher in younger patients, rose with time, and was not associated with intensive care unit status. In univariate analyses, estimates of nonsusceptibility from MYSTIC were consistently higher than those from SENTRY, but these differences disappeared in multivariate analyses, which supports the epidemiologic relevance of findings from the 2 programs, despite differences in surveillance strategies.

[1]  Clinical,et al.  Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline , 2005 .

[2]  Ronald N. Jones,et al.  Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). , 2004, Diagnostic microbiology and infectious disease.

[3]  L. Nicolle,et al.  Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  F. Dunstan,et al.  Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. , 2004, The Journal of antimicrobial chemotherapy.

[5]  D. Talan,et al.  Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. , 2004, International journal of antimicrobial agents.

[6]  F. Baquero,et al.  Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). , 2002, The Journal of antimicrobial chemotherapy.

[7]  F. LuisBavestrello,et al.  Impacto de medidas regulatorias en la tendencia de consumo comunitario de antibióticos en Chile , 2002 .

[8]  J. Richards Monitoring antibiotic resistance in urinary isolates from the community--a spotter practice model. , 2002, Communicable disease and public health.

[9]  L. Bavestrello,et al.  [Impact of regulatory measures in the trends of community consumption of antibiotics in Chile]. , 2002, Revista medica de Chile.

[10]  R. Finch,et al.  Bacterial resistance--the clinical challenge. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  S. Levy,et al.  Carriage of antibiotic-resistant fecal bacteria in Nepal reflects proximity to Kathmandu. , 2001, The Journal of infectious diseases.

[12]  S. Saint,et al.  Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology, and patient outcome. , 2001, Diagnostic microbiology and infectious disease.

[13]  L. Miller,et al.  Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  T. Hooton,et al.  Increasing Antimicrobial Resistance and the Management of Uncomplicated Community-Acquired Urinary Tract Infections , 2001, Annals of Internal Medicine.

[15]  Clyde Thornsberry,et al.  Multidrug-Resistant Urinary Tract Isolates ofEscherichia coli: Prevalence and Patient Demographics in the United States in 2000 , 2001, Antimicrobial Agents and Chemotherapy.

[16]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[17]  S. Levy,et al.  Antibiotic and antiseptic resistance: impact on public health , 2000, The Pediatric infectious disease journal.

[18]  N. Nagelkerke,et al.  Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands. , 2000, The Journal of antimicrobial chemotherapy.

[19]  J. Verhoef,et al.  Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R C George,et al.  Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis , 2000, BMJ : British Medical Journal.

[21]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[22]  M. Rodríguez-Carballeira,et al.  Emergence and Dissemination of Quinolone-ResistantEscherichia coli in the Community , 1999, Antimicrobial Agents and Chemotherapy.

[23]  P. Turner,et al.  The MYSTIC (meropenem yearly susceptibility test information collection) programme. , 1999, International journal of antimicrobial agents.

[24]  M. Pfaller,et al.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  A. Schaeffer,et al.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Livermore,et al.  Surveillance of antimicrobial resistance , 1998, BMJ.

[27]  T. O'Brien,et al.  Surveillance of antimicrobial resistance: the WHONET program. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Waitz Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[29]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.